AIT Effectiveness on AR progression
With 27.8%, significantly more
patients treated with MCT®-associated allergoids did
not receive prescriptions for symptomatic AR medication in the follow up
period vs. control group (covariate adjusted Odds Ratio (OR): 0.27;
p < 0.001). Significant
differences were also shown for allergoid 2 (19.0%, OR: 0.41;
p < 0.001) and allergoid 3 (20.4%, OR: 0.33;
p < 0.001) and therefore for the entire AIT treatment group
(20.3%, OR: 0.37; p < 0.001, see Figure 2).
In addition, the prescriptions of symptomatic AR medication in the
MCT®-associated allergoid treatment group were
significantly reduced by 24.2%
in the follow-up vs. baseline and control group (p < 0.001).
These effects could also be demonstrated for the allergoid 2, allergoid
3 and entire AIT treatment group (21.2%, 16.9%, 20.0%,
p < 0.001, see Table 2).
All endpoints were significant
for children/adolescents and adults in the individual analyses.